Investigators retrospectively analyzed visual and anatomic outcomes of patients who were attempted to be weaned off wet age-related macular degeneration therapy with either off-label intravitreal Avastin or intravitreal Eylea.
Patients in both arms received three monthly loading doses of each drug followed by a treat-and-extend protocol, with extension intervals dictated by clinical metrics including OCT findings. Eyes of patients that were extended to at least 12 weeks were then given the opportunity to have a pause in their ongoing treat-and-extend protocol (ie, a cessation in their